Intelligence · Patents
Patents expiring in 2038
Annual patent cliff calendar for 2038 — US pharmaceutical patents by expiration date.
- Patents
- 1,509
Quick answer
1,509 indexed pharmaceutical patents have expiration dates in 2038. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10080720
Pharmaceutical composition containing docetaxel
granted -
US 10080730
Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
granted -
US 10080740
Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
granted -
US 10080741
Isoxazole derivatives as FXR agonists and methods of use thereof
granted -
US 10080742
Isoxazole derivatives as FXR agonists and methods of use thereof
granted -
US 10080743
Isoxazole derivatives as FXR agonists and methods of use thereof
granted -
US 10080770
Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
granted -
US 10080799
Methods and compositions related to glycoprotein-immunoglobulin fusions
granted -
US 10080774
Oncolytic adenovirus armed with therapeutic genes
granted -
US 10080775
Peptide having skin whitening activity, and use thereof
granted -
US 10080790
Staphylococcus aureus materials and methods
granted -
US 10080803
Emulsified krill phospholipid compositions
granted -
US 10081602
Opioid agonists and uses thereof
granted -
US 10081658
Truncated HIV envelope proteins (ENV), methods and compositions related thereto
granted -
US 10081659
Adeno-associated vectors for enhanced transduction and reduced immunogenicity
granted -
US 10081668
Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection
granted -
US 10081632
Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-α]pyrazine-2-carboxamides as RSK inhibitors
granted -
US 10081811
Organic compositions to treat Beta-ENaC-related diseases
granted -
US 10082496
Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
granted -
US 10081621
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
granted -
US 10080376
Method for enhancing postprocessing content of beneficial compounds in beverages naturally containing same
granted -
US 10080739
Aryl imidazoles and their use as anti-cancer agents
granted -
US 10080745
Piericidin bacterial inhibitors
granted -
US 10080749
Multi-drug therapies for tuberculosis treatment
granted -
US 10081626
8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
granted -
US 10081669
Therapy for filovirus infection
granted -
US 10081670
Human antibodies to Ebola virus glycoprotein
granted -
US 10081661
Methods and compositions for genome engineering
granted -
EP 3378477
NEUE THERAPEUTISCHE VERWENDUNGEN VON H3-LIGANDEN
granted -
WO 2018175449
COMPOSÉS DE PROLINE AMIDE ET LEURS ANALOGUES D'AZÉTIDINE PORTANT UN RADICAL BENZYLE À SUBSTITUTION SPÉCIFIQUE
granted -
US 10087156
Methods and compositions related to retinoid receptor-selective pathway
granted -
US 10087148
Quinazolines as biogenic amine transport modulators
granted -
US 10086091
Method of preparation of biodegradable nanoparticles with recognition characteristics
granted -
US 10087230
Murine anti-NY-ESO-1 T cell receptors
granted -
US 10087169
Bicyclic PKM2 activators
granted -
US 10087143
Pyridone amides as modulators of sodium channels
granted -
US 10087181
Compound as WNT signaling inhibitor, composition, and use thereof
granted -
US 10086114
Antimicrobial solutions with enhanced stability
granted -
US 10086061
Combination purified inactivated vaccine for flaviviruses
granted -
US 10085974
Dosage and formulation
granted -
US 10085968
Multicyclic compounds and methods of use thereof
granted -
US 10085964
Ultrapure tetrahydrocannabinol-11-oic acids
granted -
US 10085935
Bee venom composition with effects of protecting and beautifying lip
granted -
US 10085986
Pyrimidinone compounds and their use
granted -
US 10085997
Method of treating microbial infections
granted -
US 10085998
Salts of potassium ATP channel openers and uses thereof
granted -
US 10085951
Curcuminoid formulations and related methods of treatment
granted -
US 10085990
Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors
granted
Frequently asked questions
How many pharma patents expire in 2038?
1,509 published patents in our USPTO index have expiration dates falling in calendar year 2038.